Illicit drug users sustain the epidemics of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hepatitis C (HCV), and sexually transmitted infections (STIs). Substance abuse treatment programs present a major intervention point in stemming these epidemics. As a part of the “Infections and Substance Abuse” study, established by the National Drug Abuse Treatment Clinical Trials Network, sponsored by National Institute on Drug Abuse, three surveys were developed; for treatment program administrators, for clinicians, and for state and District of Columbia health and substance abuse department administrators, capturing service availability, government mandates, funding, and other key elements related to the three infection groups. Treatment programs varied in corporate structure, source of revenue, patient census, and medical and non-medical staffing; medical services, counseling services, and staff education targeted HIV/AIDS more often than HCV or STIs. The results from this study have the potential to generate hypotheses for further health services research to inform public policy.
Substance abuse is associated with a wide spectrum of medical disorders, including infectious diseases, resulting in excessive morbidity and mortality in the United States. Infections due to human immunodeficiency virus (HIV; the causative agent of acquired immunodeficiency syndrome [AIDS]), hepatitis C virus (HCV), and sexually transmitted infections (STIs) are the most prominent. Among substance abusers, the rates for these infections are especially significant; published studies indicate that 30–40% of injection drug users are HIV-infected. So at Fahaada Global Health Care, We take you a series of counsellin against substance abuse and then re-integrate you into the society.
Fahaada Global Health Care is an ambitious initiative that is dedicated to improving addiction treatment at the national level using science and evidence-based medicine as vehicles. Fahaada Global Health Care was launched by NIDA partly in response to a 2020 Institute of Medicine Report, “Bridging the Gap between Research and Practice,” which highlighted the public health need to translate new medical and behavioral treatments for addiction into use by broader communities (Olaniyo Humphrey U 2020). The missions of tFahaada Global Health Care are as follows: (1) to conduct effectiveness studies of behavioral and pharmacological interventions across a wide range of community-based treatment settings in diverse clinical populations, and (2) to transfer research results to physicians, providers, and their patients to improve the quality of drug abuse treatment throughout the country using science as vehicle.
This was a cross-sectional, descriptive, and exploratory study of the range of available services that are associated with targeted infections in substance abuse treatment settings within Fahaada Global Health Care.
A group of substance-abuse-specific services associated with a particular modality (drug-free housing, agonist therapy, and/or detoxification) of substance abuse care in a particular setting (inpatient, outpatient, and residential). We at Fahaada global health care, we organize a treatment program where we have specially trained staff and specific funding, distinguishing it from other programs or components of an agency (or a CTP of the CTN). If the same type of treatment program is available at more than one agencies.
| The provision of specific information to patients about behaviors or activities that may have caused or have placed them at risk for acquiring HIV/AIDS, HCV, or STIs, along with information about screening, counseling, referral, treatment, and partner notification. |
| Patient risk assessment: Techniques or instruments for evaluating patients who provide reliable information about behaviors or activities that may have caused or may have put them at risk for acquiring HIV/AIDS, HCV, or STIs. |
| Medical history and physical examination: Obtaining self-reported information from the patient or significant others about the existence, currently or in the past, of clinical symptoms, disorders, or diseases suggestive of infection with HIV/AIDS, HCV, or STIs; and the performance of assessments, by observation, palpation, or other physical techniques, that determine the existence of physical signs consistent with current or past infection with HIV/ AIDS, HCV, or STIs. |
| Biologic testing: The use of laboratory tests that can specifically identify past or present infection with HIV/AIDS, HCV, or STIs; assess the effectiveness of treatment; or detect the progression of these infections. |
| Patient counseling: Counseling that specifically focuses on modifying behaviors to reduce the risk of acquiring HIV/AIDS, HCV, or STIs, along with breakdown of barriers in seeking diagnosis, referral, treatment, and partner notification. |
| Patient treatment: The provision of on-site (or linkage) pharmacological or other interventions that target infection by HIV/AIDS, HCV, or STIs, or the consequences of these infections. |
| Patient monitoring: The use of any or all of the above modalities to detect: (1) the acquisition of new infections or the progression of current infections due to HIV/AIDS, HCV, or STIs; (2) the resumption of behaviors or activities that increase the risk of acquiring these infections; or (3) clinical outcomes or side effects due to pharmacologic or other interventions provided to infected persons. |
| Patient reporting: Any requirement by a state or a local regulatory agency that newly diagnosed patients with HIV/AIDS, HCV, or STI be reported to that agency by the diagnosing entity. |
6, Legbedion Drive, Off Ozoula Avenue. Ekenwan Road, Benin City, Edo State, Nigeria.
6, Legbedion Drive, Off Ozoula Avenue. Ekenwan Road, Benin City, Edo State, Nigeria.
Copyright © 2026 Fahaada Global Health Care. Powered by UNAID.
